222
Participants
Start Date
May 31, 2008
Primary Completion Date
June 30, 2012
Study Completion Date
December 31, 2012
XL184
Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
University of Virginia Health System, Charlottesville
Duke University, The Preston Robert Tisch Brain Tumor Center, Durham
Henry Ford Health System, Detroit
University of Texas M.D. Anderson Cancer Center, Houston
University of California, Los Angeles, Los Angeles
University of California, San Francisco, San Francisco
University of Washington, Seattle
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Exelixis
INDUSTRY